{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for l root_references_url in Reference URL (approximate match)
Status:
Possibly Marketed Outside US
Source:
ANDA078003
(1989)
Source URL:
First approved in 1988
Source:
21 CFR 333A
Source URL:
Class:
POLYMER
Status:
Investigational
Source:
NCT02282215: Phase 2 Interventional Completed Acute Myeloid Leukemia
(2014)
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
Other
Class:
STRUCTURALLY DIVERSE
Status:
US Previously Marketed
Source:
21 CFR 310.545(a)(24)(i) menstrual/diuretic oil of erigeron
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
M020
(2024)
Source URL:
First approved in 2024
Source:
M020
Source URL:
Class:
STRUCTURALLY DIVERSE
Status:
Possibly Marketed Outside US
Source:
GLUCOSA FACTOR by New World Holdings, Inc.
(2020)
Source URL:
First approved in 2020
Source:
GLUCOSA FACTOR by New World Holdings, Inc.
Source URL:
Class:
STRUCTURALLY DIVERSE
